市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | SpyGlass Pharma, Inc. | - | - |
AIStockmoo 评分
1.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.83 |
|
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nea Management Company, Llc | 30 Jun 2026 | 7,392,301 |
| Sands Capital Alternatives, Llc | 30 Jun 2026 | 2,500,012 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 2,109,953 |
| Vestal Point Capital, Lp | 30 Jun 2026 | 670,000 |
| Deerfield Management Company, L.P. | 30 Jun 2026 | 550,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 131,586 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合